is tirzepatide on shortage list FDA resolves shortage, impacting compounding pharmacies FDA's GLP-1 decision kicks off

(2012) 7:e49683

Eli Lillys GLP-1 offering, tirzepatide, launched shortly after (as Mounjaro for T2D in 2022 and Zepbound for obesity in 2023), demonstrated greater HbA1c reduction and up to a 20% placebo-adjusted weight loss

The notification data may be processed for the purposes of sending you newsletters

These medications bind to the same receptors in the body, which allows them to produce similar effects

Get in Touch Questions

do not use if you have a history of severe gastrointestinal disease Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness)